Quantitative Real-time Polymerase Chain Reaction Detection of Lymph Node Lung Cancer Micrometastasis Using Carcinoembryonic Antigen Marker

STUDY OBJECTIVES The survival of patients with surgically resected stage I non-small cell lung cancer (NSCLC) is not optimal, probably because of unsuspected systemic occult tumor dissemination. The current applied technologies and methods for scanning the body and examining lymph nodes for tumor cells have broadly recognized limitations. Several studies have reported that it is possible to detect occult lymph node metastases (micrometastases) using more sensitive methods such as immunohistochemistry or molecular technology. The aim of our study was to evaluate the utility of quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR) for carcinoembryonic antigen (CEA) messenger RNA (mRNA) for detection of lymph node micrometastases and its impact on disease-free interval. METHODS Quantitative real-time RT-PCR for CEA mRNA was performed on primary lung tumors and regional lymph nodes from 44 surgically resected NSCLC patients classified as clinical stage I. Fourteen lymph nodes from five patients without malignancy were used as controls. The end point of clinical analysis was cancer recurrence. Average follow-up was 22.5 months. RESULTS CEA mRNA was detected in all but four lymph nodes used as controls. All primary tumors were positive for CEA mRNA. Of 261 lymph nodes analyzed, 35 lymph nodes (13.4%) showed CEA mRNA levels higher than those detected in control lymph nodes and were considered positive for micrometastasis. Survival analysis by micrometastases showed less cancer recurrences in patients with lymph nodes negative for CEA mRNA (log rank, 5.3; p = 0.021). Among tumor type, tumor grading, age, sex, and molecularly detected lymph node micrometastases, the most powerful predictor of cancer recurrences was the presence of micrometastases (Cox proportional hazard, 3.3; p = 0.027). CONCLUSION Quantitative real-time RT-PCR for CEA mRNA can be applied for detection of micrometastases in lymph nodes. This technique may be an appropriate tool in predicting cancer recurrences, and further studies are warranted to determine the most useful clinical applications.

[1]  J. Herndon,et al.  Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  Zhou Wang,et al.  Lymph node occult micrometastasis in patients with non-small cell lung carcinoma: genetic diagnosis and its impact on prognosis. , 2003, Ai zheng = Aizheng = Chinese journal of cancer.

[3]  A. Marchevsky,et al.  The prognostic significance of intranodal isolated tumor cells and micrometastases in patients with non-small cell carcinoma of the lung. , 2003, The Journal of thoracic and cardiovascular surgery.

[4]  V. Rusch,et al.  Detection and measurement of occult disease for the prognosis of solid tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Marchetti,et al.  Prediction of Survival in Stage I Lung Carcinoma Patients by Telomerase Function Evaluation , 2002, Laboratory Investigation.

[6]  M. Brock,et al.  Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study. , 2002, The Journal of thoracic and cardiovascular surgery.

[7]  T. D’amico Molecular biologic substaging of non-small cell lung cancer. , 2002, The Journal of thoracic and cardiovascular surgery.

[8]  G. Patterson,et al.  Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761. , 2002, The Journal of thoracic and cardiovascular surgery.

[9]  S. Bustin Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. , 2000, Journal of molecular endocrinology.

[10]  D. Harpole,et al.  Molecular biologic substaging of stage I lung cancer according to gender and histology. , 2000, The Annals of thoracic surgery.

[11]  J. Rosai,et al.  Molecular detection of micrometastases and circulating tumor cells in solid tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  I. Bièche,et al.  Novel approach to quantitative polymerase chain reaction using real‐time detection: Application to the detection of gene amplification in breast cancer , 1998, International journal of cancer.

[13]  D. Cole,et al.  Efficacy of reverse transcriptase-polymerase chain reaction screening for micrometastic disease in axillary lymph nodes of breast cancer patients. , 1998, The American surgeon.

[14]  K. Pantel,et al.  Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases , 1996, The Lancet.

[15]  Clive R. Taylor,et al.  Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. , 1995 .

[16]  J. Izbicki,et al.  Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Hughes,et al.  FAILURE OF TETRACHLORODECAOXYGEN ANION COMPLEX TO ASSIST WOUND HEALING , 1989, The Lancet.

[18]  R. Stahel,et al.  Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Powles,et al.  DETECTION OF MICROMETASTASES IN PATIENTS WITH PRIMARY BREAST CANCER , 1983, The Lancet.

[20]  J. Izbicki,et al.  Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Jamel Chelly,et al.  Illegitimate transcription: Its use in the study of inherited disease , 1992, Human mutation.